Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a biotechnology leader developing innovative therapies for rare diseases, including hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta syndrome (APDS). This page provides investors and healthcare professionals with direct access to the company's latest press releases and official announcements.
Track PHARM's progress through updates on clinical trials, regulatory milestones, and commercialization efforts for therapies like RUCONEST® and Joenja®. Our curated news feed ensures you stay informed about earnings reports, strategic partnerships, and market expansion initiatives without extraneous information.
Discover updates categorized for quick navigation, including product development breakthroughs, financial performance disclosures, and operational strategy refinements. All content is sourced directly from Pharming's verified communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PHARM's evolving story in rare disease treatment. Check regularly for new developments that demonstrate the company's commitment to addressing unmet medical needs through biopharmaceutical innovation.
Pharming Group has announced the dosing of the first patient in a Phase II clinical trial evaluating leniolisib for common variable immunodeficiency (CVID) with immune dysregulation. The trial is a single-arm, open-label study targeting approximately 20 patients aged 12 and older across sites in the US, UK, and EU.
The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy in CVID patients with immune dysregulation. CVID represents the largest group of symptomatic primary immunodeficiency patients, with a global prevalence of approximately 39 patients per million for the targeted population.
Led by Dr. Jocelyn Farmer at Beth Israel Lahey Health, the trial focuses on patients with CVID diagnosis, lymphoproliferation evidence, and additional immune dysregulation manifestations. CVID patients with immune dysregulation face an 11-fold higher mortality rate compared to those with infectious manifestations alone. Leniolisib, currently marketed as Joenja® in the U.S. for APDS treatment, represents a potential therapy for this unmet medical need.
Pharming Group reported strong financial results for Q4 and full year 2024, with total revenues increasing 21% to US$297.2 million, exceeding guidance. This growth was driven by record RUCONEST® revenue of US$252.2 million (up 11%) and strong Joenja® performance of US$45.0 million (up 147%).
Q4 2024 highlights include total revenues of US$92.7 million (up 14%) and operating profit increase to US$6.7 million from US$1.1 million in Q4 2023. The company generated operating profit and positive cash flows for two consecutive quarters.
Key developments include two ongoing Phase II trials of leniolisib for additional primary immunodeficiencies, the completion of Abliva AB acquisition adding KL1333 to the pipeline, and the appointment of Fabrice Chouraqui as CEO. The company provided 2025 revenue guidance of US$315-335 million.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) announced that shareholders approved all proposals at their Extraordinary General Meeting (EGM). Fabrice Chouraqui has been appointed as Executive Director and Chief Executive Officer for a four-year term, effective immediately. He succeeds Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.
Shareholders also approved specific components of Chouraqui's remuneration package. The company has made available a recording of the webcast and presentation slides from the EGM on their website's Investor Relations section.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced its participation in the upcoming 37th Annual Roth Conference in Dana Point, California, scheduled for March 16-18, 2025.
The company's Chief Medical Officer Anurag Relan and VP Investor Relations and Corporate Communications Michael Levitan will engage in a fireside chat and Q&A session on March 17, 2025, at 1:30 PM PT/21:30 CET.
Investors interested in one-on-one meetings with Pharming's management team can arrange appointments through the company's Investor Relations team or their Roth representative.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced it will release its preliminary (unaudited) fourth quarter and full year 2024 financial results on Thursday, March 13, 2025. The company will host an analyst and investor presentation at 13:30 CET/08:30 am EDT on the same day.
The presentation will include a conference call for which participants must register in advance to receive dial-in information and a unique PIN. Questions will only be taken from dial-in attendees. A live webcast of the presentation will also be available through advance registration.
Pharming Technologies B.V. has increased its ownership in Abliva AB to 92.70% following its recommended cash offer of SEK 0.45 per share announced on December 15, 2024. During the initial acceptance period ending February 7, 2025, shareholders representing 87.71% of Abliva's shares accepted the offer. An additional 2.94% of shares were tendered during the extended acceptance period, and Pharming acquired 2.05% of shares outside the offer.
The company has further extended the acceptance period until March 6, 2025, to allow remaining shareholders to participate. Settlement for shares tendered during this extended period is expected around March 12, 2025. Pharming plans to initiate a compulsory acquisition procedure for remaining shares and will pursue delisting Abliva from Nasdaq Stockholm.
Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a presentation by CEO Sijmen de Vries and CMO Anurag Relan on Wednesday, February 12 at 08:40 ET/14:40 CET.
Investors can access both the live webcast and replay of the presentation through the 'Upcoming Events' and 'News' sections of Pharming's website. Those interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their Oppenheimer representative.
Pharming Technologies B.V. has successfully completed its recommended cash offer to Abliva AB shareholders, achieving 87.7% acceptance of total shares at SEK 0.45 per share. Although the original offer was conditional upon reaching 90% ownership, Pharming has waived this condition and declared the offer unconditional.
Settlement for shares tendered up to February 7, 2025, is expected around February 14, 2025. The acceptance period has been extended to February 20, 2025, at 15:00 CET, with settlement for this extended period expected around February 27, 2025.
Additionally, Pharming has acquired all outstanding warrants from holders at prices ranging between SEK 0.03-0.054 per warrant. If Pharming reaches 90% ownership, it plans to initiate a compulsory acquisition of remaining shares and pursue delisting from Nasdaq Stockholm.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) has announced an Extraordinary General Meeting (EGM) scheduled for March 4, 2025, at 14:00 CET. The primary purpose is to appoint Fabrice Chouraqui as Executive Director and Chief Executive Officer for a four-year term, succeeding Sijmen de Vries. The agenda includes approving components of Chouraqui's remuneration package.
The meeting will be held physically at the Corpus Congress Centre in Oegstgeest, Netherlands, with shareholders having the option to attend in person or follow via live webcast. All relevant documents, including the Notice to Convene, Explanatory Notes, and voting information, are available on the company's website under the Investors/Shareholder Meetings section.
Pharming Group has nominated Fabrice Chouraqui as its new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. The appointment will be for a four-year term, subject to shareholder approval at an upcoming Extraordinary General Meeting. De Vries will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.
Chouraqui brings extensive global pharmaceutical and biotechnology experience. He previously served as CEO-Partner at Flagship Pioneering and CEO of Cellarity, Inc., where he raised over $250M. His prior roles include President of Novartis Pharmaceuticals USA (2016-2019) and various leadership positions at Bristol-Myers Squibb. He holds an MBA from INSEAD and a Doctorate in Pharmacy from the University of Paris V.
